Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial

BMC Endocrine Disorders

Christopher M Reid²  Gayle S Savige²  Melinda T Coughlan¹  Nicole J Kellow² 

[1] Department of Medicine, Central Clinical School, Monash University, Alfred Medical Research & Education Precinct, Melbourne, Victoria 3004, Australia;Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria 3004, Australia

关键词: Inflammation;    Insulin resistance;    Type 2 diabetes mellitus;    Gut microbiota;    Prebiotics;    Maillard reaction;    Advanced glycation end products;   

Others  :  864908
DOI  :  10.1186/1472-6823-14-55

 received in 2013-09-24, accepted in 2014-06-30,  发布年份 2014

【 摘 要 】

Background

Advanced glycation endproducts (AGEs) contribute to the development of vascular complications of diabetes and have been recently implicated in the pathogenesis of diabetes. Since AGEs are generated within foodstuffs upon food processing, it is increasingly recognised that the modern diet is replete with AGEs. AGEs are thought to stimulate chronic low-grade inflammation and promote oxidative stress and have been linked to the development of insulin resistance. Simple therapeutic strategies targeted at attenuating the progression of chronic low-grade inflammation and insulin resistance are urgently required to prevent or slow the development of type 2 diabetes in susceptible individuals. Dietary modulation of the human colonic microbiota has been shown to confer a number of health benefits to the host, but its effect on advanced glycation is unknown. The aim of this article is to describe the methodology of a double-blind placebo-controlled randomised crossover trial designed to determine the effect of 12 week consumption of a prebiotic dietary supplement on the advanced glycation pathway, insulin sensitivity and chronic low-grade inflammation in adults with pre-diabetes.

Methods/Design

Thirty adults with pre-diabetes (Impaired Glucose Tolerance or Impaired Fasting Glucose) aged between 40–60 years will be randomly assigned to receive either 10 grams of prebiotic (inulin/oligofructose) daily or 10 grams placebo (maltodextrin) daily for 12 weeks. After a 2-week washout period, study subjects will crossover to receive the alternative dietary treatment for 12 weeks. The primary outcome is the difference in markers of the advanced glycation pathway carboxymethyllysine (CML) and methylglyoxal (MG) between experimental and control treatments. Secondary outcomes include HbA_1c, insulin sensitivity, lipid levels, blood pressure, serum glutathione, adiponectin, IL-6, E-selectin, myeloperoxidase, C-reactive protein, Toll-like Receptor 4 (TLR4), soluble receptor for AGE (sRAGE), urinary 8-isoprostanes, faecal bacterial composition and short chain fatty acid profile. Anthropometric measures including BMI and waist circumference will be collected in addition to comprehensive dietary and lifestyle data.

Discussion

Prebiotics which selectively stimulate the growth of beneficial bacteria in the human colon might offer protection against AGE-related pathology in people at risk of developing type 2 diabetes.

Trial registration

Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12613000130763.

【 授权许可】

   
2014 Kellow et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Henle T: Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 2005, 29(4):313-322.
• [2]Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
• [3]Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G: The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 2011, 7(5):313-324.
• [4]Kotani K, Sakane N: C-reactive protein and reactive oxygen metabolites in subjects with metabolic syndrome. J Int Med Res 2012, 40(3):1074-1081.
• [5]Thornalley PJ: Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 2005, 1043:111-117.
• [6]Avery NC, Bailey AJ: The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol 2006, 54(7):387-395.
• [7]Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF: Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005, 289(2):F420-F430.
• [8]Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM: RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009, 20(4):742-752.
• [9]Yim MB, Yim HS, Lee C, Kang SO, Chock PB: Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci 2001, 928:48-53.
• [10]Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96(3):1395-1403.
• [11]Morita M, Yano S, Yamaguchi T, Sugimoto T: Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells. J Diabetes Complications 2013, 27(1):11-15.
• [12]Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imaizumi T: Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012, 30(1):42-48.
• [13]Tan KC, Shiu SW, Wong Y, Tam X: Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev 2011, 27(5):488-492.
• [14]Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H: Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005, 1043:461-466.
• [15]Fiory F, Lombardi A, Miele C, Giudicelli J, Beguinot F, Van Obberghen E: Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 2011, 54(11):2941-2952.
• [16]Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V, Webster DE, Miyazaki J, Kay TW, Slattery RM, Kaye DM, Drew BG, Kingwell BA, Fourlanos S, Groop PH, Harrison LC, Knip M, Forbes JM: Advanced glycation end products are direct modulators of beta-cell function. Diabetes 2011, 60(10):2523-2532.
• [17]Birlouez-Aragon I, Saavedra G, Tessier FJ, Galinier A, Ait-Ameur L, Lacoste F, Niamba CN, Alt N, Somoza V, Lecerf JM: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010, 91(5):1220-1226.
• [18]Tessier FJ, Birlouez-Aragon I: Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids 2012, 42(4):1119-1131.
• [19]Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H: Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005, 54(8):2314-2319.
• [20]Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 2012, 109(39):15888-15893.
• [21]Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011, 34(7):1610-1616.
• [22]Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, Holst JJ, Nielsen J, de Courten B, Dragsted LO, Bugel S: Consumption of a diet low in advanced glycation endproducts for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014, 37(1):88-95.
• [23]Luevano-Contreras C, Garay-Sevilla ME, Wrobel K, Malacara JM: Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 2013, 52(1):22-26.
• [24]Harcourt BE, Sourris KC, Coughlan MT, Walker KZ, Dougherty SL, Andrikopoulos S, Morley AL, Thallas-Bonke V, Chand V, Penfold SA, de Courten MP, Thomas MC, Kingwell BA, Bierhaus A, Cooper ME, Courten B, Forbes JM: Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 2011, 80(2):190-198.
• [25]Kellow NJ, Savige GS: Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. Eur J Clin Nutr 2013, 67(3):239-248.
• [26]Round JL, Mazmanian SK: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9(5):313-323.
• [27]Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK: High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010, 5(8):e12191.
• [28]Diamant M, Blaak EE, de Vos WM: Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 2011, 12(4):272-281.
• [29]Backhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007, 104(3):979-984.
• [30]Hill MJ: Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997, 6(Suppl 1):S43-S45.
• [31]Macfarlane GT, Macfarlane S: Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol 2011, 45(Suppl):S120-S127.
• [32]Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, Yu P, Zhao C, Li L, Zhou A, Wang J, Moore JE, Millar BC, Xu J: Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010, 61(1):69-78.
• [33]Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sorensen SJ, Hansen LH, Jakobsen M: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010, 5(2):e9085.
• [34]Mills DJ, Tuohy KM, Booth J, Buck M, Crabbe MJ, Gibson GR, Ames JM: Dietary glycated protein modulates the colonic microbiota towards a more detrimental composition in ulcerative colitis patients and non-ulcerative colitis subjects. J Appl Microbiol 2008, 105(3):706-714.
• [35]Nakamura YK, Omaye ST: Metabolic diseases and pro- and prebiotics: mechanistic insights. Nutr Metab (Lond) 2012, 9(1):60.
• [36]Quigley EM: Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am 2011, 40(1):207-222.
• [37]Delzenne NM, Neyrinck AM, Backhed F, Cani PD: Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011, 7(11):639-646.
• [38]Colagiuri SDD, Girgis S, Colagiuri R: National evidence based guideline for case detection and diagnosis of type 2 diabetes. Canberra, Australia: Diabetes Australia and the National Health and Medical Research Council; 2009.
• [39]Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L: Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr 2011, 141(9):1726-1730.
• [40]Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M: Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis 2009, 205(2):590-594.
• [41]Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D: Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007, 30(3):670-676.
• [42]Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L: Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 2009, 57(10):1874-1880.
• [43]Kolida S, Meyer D, Gibson GR: A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr 2007, 61(10):1189-1195.
• [44]Causey JL: Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. Nutr Res 2000, 20(2):191-201.
• [45]Lecerf JM, Depeint F, Clerc E, Dugenet Y, Niamba CN, Rhazi L, Cayzeele A, Abdelnour G, Jaruga A, Younes H, Jacobs H, Lambrey G, Abdelnour AM, Pouillart PR: Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 2012, 108(10):1847-1858.
• [46]Hull GLJ, Ames JM, Cuskelly GJ: NEpsilon-(carboxymethyl)lysine content of foods commonly consumed in a Western style diet. Food Chem 2012, 131:170-174.
• [47]Bihuniak JD, Simpson CA, Sullivan RR, Caseria DM, Kerstetter JE, Insogna KL: Dietary protein-induced increases in urinary calcium are accompanied by similar increases in urinary nitrogen and urinary urea: a controlled clinical trial. J Acad Nutr Diet 2013, 113(3):447-451.
• [48]Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003, 35(8):1381-1395.
• [49]Boehm BO, Schilling S, Rosinger S, Lang GE, Lang GK, Kientsch-Engel R, Stahl P: Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004, 47(8):1376-1379.
• [50]Zhang X, Frischmann M, Kientsch-Engel R, Steinmann K, Stopper H, Niwa T, Pischetsrieder M: Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med 2005, 43(5):503-511.
• [51]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
• [52]Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23(1):57-63.
• [53]Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R: Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol 2002, 68(11):5445-5451.
• [54]Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM: Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013, 62(8):1112-1121.
• [55]Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P: Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 2009, 101(4):541-550.
• [56]Wang RF, Cao WW, Cerniglia CE: PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Appl Environ Microbiol 1996, 62(4):1242-1247.
• [57]Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD: Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013, 110(22):9066-9071.
• [58]Sebekova K, Boor P, Valachovicova M, Blazicek P, Parrak V, Babinska K, Heidland A, Krajcovicova-Kudlackova M: Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Mol Nutr Food Res 2006, 50(9):858-868.
• [59]Vlassara H, Uribarri J, Cai W, Striker G: Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci 2008, 1126:46-52.
• [60]Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004, 104(8):1287-1291.
• [61]Shen Q, Chen YA, Tuohy KM: A comparative in vitro investigation into the effects of cooked meats on the human faecal microbiota. Anaerobe 2010, 16(6):572-577.
• [62]Connolly ML, Lovegrove JA, Tuohy KM: In vitro fermentation characteristics of whole grain wheat flakes and the effect of toasting on prebiotic potential. J Med Food 2012, 15(1):33-43.
• [63]De Preter V, Hamer HM, Windey K, Verbeke K: The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health? Mol Nutr Food Res 2011, 55(1):46-57.
• [64]Faist V, Erbersdobler HF: Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 2001, 45(1):1-12.
• [65]Rapin JR, Wiernsperger N: Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine. Clinics (Sao Paulo) 2010, 65(6):635-643.
• [66]Scheppach W: Effects of short chain fatty acids on gut morphology and function. Gut 1994, 35(1 Suppl):S35-S38.
• [67]Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, Hahm JS: Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci 2006, 51(4):693-697.
• [68]Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A: Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011, 17(12):1519-1528.
• [69]Delzenne NM, Cani PD: Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr 2011, 31:15-31.
• [70]Russo F, Linsalata M, Clemente C, Chiloiro M, Orlando A, Marconi E, Chimienti G, Riezzo G: Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. Nutr Res 2012, 32(12):940-946.
• [71]Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58(8):1091-1103.
• [72]Cani PD: Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin Microbiol Infect 2012, 18(Suppl 4):50-53.
• [73]Schalkwijk CG, Miyata T: Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids 2012, 42(4):1193-1204.
• [74]Anderson MM, Heinecke JW: Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003, 52(8):2137-2143.
• [75]Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE: Diabetes and advanced glycoxidation end products. Diabetes Care 2006, 29(6):1420-1432.
• [76]Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD: High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137(5):1716-1724. e1711-1712
• [77]Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M: The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010, 53(4):606-613.
• [78]Esteve E, Ricart W, Fernandez-Real JM: Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care 2011, 14(5):483-490.
• [79]Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56(7):1761-1772.
• [80]Priebe MG, Wang H, Weening D, Schepers M, Preston T, Vonk RJ: Factors related to colonic fermentation of nondigestible carbohydrates of a previous evening meal increase tissue glucose uptake and moderate glucose-associated inflammation. Am J Clin Nutr 2010, 91(1):90-97.
• [81]Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292(3):E740-E747.
• [82]Amar J: Energy intake is associated with endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 2010, 59:9.
• [83]Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50(11):2374-2383.
• [84]Lin MY, Yen CL: Inhibition of lipid peroxidation by Lactobacillus acidophilus and Bifidobacterium longum. J Agric Food Chem 1999, 47(9):3661-3664.
• [85]Yen CH, Kuo YW, Tseng YH, Lee MC, Chen HL: Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents–a placebo-controlled, diet-controlled trial. Nutrition 2011, 27(3):323-328.
• [86]Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR: Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461(7268):1282-1286.
• [87]Vinolo MA, Rodrigues HG, Nachbar RT, Curi R: Regulation of inflammation by short chain fatty acids. Nutrients 2011, 3(10):858-876.
• [88]Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM: Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 2010, 16(7):1138-1148.
• [89]Erridge C, Attina T, Spickett CM, Webb DJ: A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007, 86(5):1286-1292.
• [90]Krogh-Madsen R, Plomgaard P, Akerstrom T, Moller K, Schmitz O, Pedersen BK: Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab 2008, 294(2):E371-E379.
• [91]Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, Vieira AT, Kranich J, Mackay CR: Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev 2012, 245(1):164-176.
• [92]Maslowski KM, Mackay CR: Diet, gut microbiota and immune responses. Nat Immunol 2011, 12(1):5-9.
• [93]Musso G, Gambino R, Cassader M: Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011, 62:361-380.
• [94]Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, Egawa K, Horikawa C, Kitagawa Y, Kiso Y, Kimura S, Sakane N: Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009, 54(3):197-201.
• [95]Cani PD, Joly E, Horsmans Y, Delzenne NM: Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2006, 60(5):567-572.
• [96]Parnell JA, Reimer RA: Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009, 89(6):1751-1759.
• [97]Ruijschop RBA, te Giffela MC: Satiety effects of a dairy beverage fermented with propionic acid bacteria. Int Dairy J 2008, 18:5.
• [98]Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101(44):15718-15723.
• [99]Aronsson L, Huang Y, Parini P, Korach-Andre M, Hakansson J, Gustafsson JA, Pettersson S, Arulampalam V, Rafter J: Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One 2010., 5(9) doi:10.1371/journal.pone.0013087
• [100]Dewulf EM, Cani PD, Neyrinck AM, Possemiers S, Van Holle A, Muccioli GG, Deldicque L, Bindels LB, Pachikian BD, Sohet FM, Mignolet E, Francaux M, Larondelle Y, Delzenne NM: Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 2011, 22(8):712-722.
• [101]Vyas U, Ranganathan N: Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterology Res Pract 2012, 2012:872716.
• [102]Mehta R, Shangari N, O'Brien PJ: Preventing cell death induced by carbonyl stress, oxidative stress or mitochondrial toxins with vitamin B anti-AGE agents. Mol Nutr Food Res 2008, 52(3):379-385.
• [103]Stoyanova S, Geuns J, Hideg E, Van Den Ende W: The food additives inulin and stevioside counteract oxidative stress. Int J Food Sci Nutr 2011, 62(3):207-214.
• [104]Wu WT, Chen HL: Effects of konjac glucomannan on putative risk factors for colon carcinogenesis in rats fed a high-fat diet. J Agric Food Chem 2011, 59(3):989-994.
• [105]Todesco T, Rao AV, Bosello O, Jenkins DJ: Propionate lowers blood glucose and alters lipid metabolism in healthy subjects. Am J Clin Nutr 1991, 54(5):860-865.
• [106]Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J: Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009, 58(7):1509-1517.
• [107]Cani PD, Hoste S, Guiot Y, Delzenne NM: Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr 2007, 98(1):32-37.
• [108]Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R: Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006, 55(5):1484-1490.
• [109]Uchiki T, Weikel KA, Jiao W, Shang F, Caceres A, Pawlak D, Handa JT, Brownlee M, Nagaraj R, Taylor A: Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). Aging Cell 2012, 11(1):1-13.
• [110]Garcia AL, Otto B, Reich SC, Weickert MO, Steiniger J, Machowetz A, Rudovich NN, Mohlig M, Katz N, Speth M, Meuser F, Doerfer J, Zunft HJ, Pfeiffer AH, Koebnick C: Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance. Eur J Clin Nutr 2007, 61(3):334-341.
• [111]Lu ZX, Walker KZ, Muir JG, O'Dea K: Arabinoxylan fibre improves metabolic control in people with Type II diabetes. Eur J Clin Nutr 2004, 58(4):621-628.
• [112]Magliano DJ, Peeters A, Vos T, Sicree R, Shaw J, Sindall C, Haby M, Begg SJ, Zimmet PZ: Projecting the burden of diabetes in Australia–what is the size of the matter? Aust N Z J Public Health 2009, 33(6):540-543.